Key facts
- OrthoReBirth’s last known valuation is $11.0M (Mar 2024).
- It has raised $28.0M; the latest was PE Growth/Expansion in Feb 2026.
- Notable investors include Mizuho Capital, Nissay Capital, Innovation Engine, Hiroshima Capital Partners, Awagin Capital — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for OrthoReBirth
- ·The full record, as it builds
Funding rounds
No funding rounds for OrthoReBirth are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OrthoReBirth
Manufacturer of medical synthetics intended to offer regenerative medicines. The company's synthetics involve a non-solid artificial bone composed of intertangled chunks of very fine cotton-like fibers that act as bone void filler for the repair of bone defects, enabling healthcare providers with an easy-to-use and handle filling material that can be used in a variety of applications.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2011
- Employees
- 5
- Website
- orthorebirth.com/
- Ownership
- Privately Held (backing)
OrthoReBirth doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrthoReBirth shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrthoReBirth in its N-PORT filings yet. We sweep new filings monthly.